CagriSema: Cagrilintide + Semaglutide, Phase III Data, and Weight Loss vs GLP-1 Monotherapy

CagriSema: Cagrilintide + Semaglutide, Phase III Data, and Weight Loss vs GLP-1 Monotherapy

CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 receptor agonist) developed by Novo Nordisk. The combination was designed to achieve additive or synergistic weight reduction by targeting two complementary satiety pathways simultaneously. Phase III data published in 2025 confirmed this hypothesis with weight loss figures that significantly exceed semaglutide monotherapy.

Mechanism: Dual Pathway Satiety

Semaglutide acts on GLP-1 receptors in the hypothalamus, brainstem, and GI tract — delaying gastric emptying, reducing appetite, and improving glycemic control through GLP-1’s incretin effects. The mechanism and clinical profile of semaglutide are well-established from SUSTAIN and STEP trial programs.

Cagrilintide is a long-acting amylin analog. Amylin is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors (AMY1-3, formed by calcitonin receptor + RAMP proteins) in the area postrema and hypothalamus. Its primary actions are complementary to GLP-1: reducing postprandial glucagon, slowing gastric emptying through a distinct mechanism, and suppressing appetite via brainstem circuits not fully overlapping with GLP-1 pathways. Native amylin has a short half-life; cagrilintide extends this to approximately 7 days, enabling once-weekly co-formulation with semaglutide.

The synergy hypothesis rests on non-overlapping receptor targets converging on appetite and energy balance. Two separate satiety signals, amplified together, produce greater weight loss than either alone — consistent with how the physiology works in lean individuals who have both GLP-1 and amylin signaling at adequate levels.

Phase III Evidence: REDEFINE 1

REDEFINE 1 (Novo Nordisk, 2025) enrolled 3,400 adults with obesity (BMI ≥30) or overweight with comorbidities. Participants received CagriSema 2.4 mg/2.4 mg weekly versus semaglutide 2.4 mg alone versus placebo over 68 weeks.

Key results:

• CagriSema: 22.7% mean body weight reduction from baseline
• Semaglutide monotherapy arm: 16.1% (consistent with STEP 1)
• Placebo: 2.3%
• CagriSema achieved ≥20% weight loss in approximately 40% of participants versus ~15% with semaglutide alone
• Cardiovascular risk markers (BP, lipids, HbA1c) improved more in the CagriSema arm

Gastrointestinal side effects (nausea, vomiting) were more frequent with CagriSema than semaglutide alone, consistent with combining two agents that affect gastric motility. The increased AE burden was manageable and did not substantially affect discontinuation rates versus the semaglutide monotherapy arm.

Clinical Relevance

The 22.7% figure is significant in context. Bariatric surgery achieves 25–30% weight loss at 1 year for most procedures. CagriSema approaches surgical outcomes with a weekly injection and no operative risk — a threshold that changes the clinical calculus for severe obesity management.

The comparison to tirzepatide (GIP/GLP-1 dual agonist, 20–22% weight loss at max dose) is relevant: CagriSema and tirzepatide appear roughly equivalent in weight loss magnitude but achieve it through different receptor mechanisms. The competitive landscape for best-in-class obesity pharmacology now includes multiple agents exceeding 20% weight loss.

For type 2 diabetes applications, CagriSema’s amylin + GLP-1 dual mechanism provides glycemic control through complementary pathways — postprandial glucagon suppression from both agents, delayed gastric emptying, and beta cell preservation via GLP-1’s incretin effect.

Bottom Line

CagriSema’s Phase III data delivers the additive weight loss the mechanism predicted — 22.7% versus 16.1% for semaglutide alone, approaching bariatric surgery outcomes. The dual amylin/GLP-1 mechanism is pharmacologically coherent. GI tolerability is higher than semaglutide monotherapy but not prohibitive. This is a clinically meaningful advance over single-pathway GLP-1 therapy with Phase III backing at scale.